| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C,unstable in solution, ready to use. | [solubility ]
DMSO : 100 mg/mL (137.74 mM; Need ultrasonic) | [form ]
Solid | [color ]
White to off-white | [InChIKey]
DASWEROEPLKSEI-CMHCZSPYSA-N |
| Hazard Information | Back Directory | [Uses]
MMAE-d8 is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor. | [Biological Activity]
D8-MMAE (D8-Monomethyl auristatin E) is a deuterated labeled MMAE. MMAE is a tubulin inhibitor that inhibits mitosis. | [in vivo]
Intratumoral MMAE concentrations consistently correlates with the extent of tumor growth inhibition in tumor xenograft models. IHC analysis reveals that nonbinding control-treated tumors consist of both CD30 + and CD30 - cells, presumably because they do not kill either CD30 + or CD30 - Karpas 299 cells. Only CD30 - cells are found in cAC10-vcMMAF-treated tumors, illustrating that cAC10-vcMMAF eliminates most CD30 + cells. Interestingly, the two tumors that relapses from cAC10-vcMMAE treatment are also found to be CD30 - by the end of study, indicating a small fraction of CD30 - cells might have escaped from bystander killing in these two remaining tumors. p> | [target]
| [IC 50]
Auristatin | [storage]
Store at -20°C,unstable in solution, ready to use. | [References]
[1] Li F, et al. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Cancer Res. 2016 May 1;76(9):2710-9. DOI:10.1158/0008-5472.CAN-15-1795 |
|
|